| Project/Area Number |
26350528
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Biomedical engineering/Biomaterial science and engineering
|
|---|
| Research Institution | Osaka City University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
Masunaga Shin-ichiro 京都大学, 原子炉実験所, 教授 (80238914)
MAzuma Hideki 大阪市立大学, 大学院工学研究科, 講師 (80311918)
|
|---|
| Project Period (FY) |
2014-04-01 – 2017-03-31
|
| Project Status |
Completed (Fiscal Year 2016)
|
| Budget Amount *help |
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2016: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2015: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2014: ¥2,470,000 (Direct Cost: ¥1,900,000、Indirect Cost: ¥570,000)
|
|---|
| Keywords | 薬物送達システム / ホウ素中性子捕捉療法 / がん治療 / 超分子化学 / 包接化合物 / ターゲティング / ナノメディシン / シクロデキストリン / 超分子 / がん転移 / 水溶化剤 / 転移抑制 / 抗がん剤 / 生体材料 / ナノ材料 / 癌 / ナノバイオ |
|---|
| Outline of Final Research Achievements |
A novel water-soluble complex between boron cluster carborane-kojic acid conjugate(CKA) and hydroxylpropyl-beta-cyclodextrin (HP-betaCD) hve been prepared. It was revealed that CKA-HP-betaCD complex inhibited the metastasis of melanoma cells in vivo. It was suggested that the inhibitory ability of CKA to HIF-1alpha contributed to suppress the matastasis. Furthermore, in this study, the quantitative evaluation of the CKA’s inhibitory ability was carried out by quantitative real-time PCR in vivo. From the results of real-time PCR, CKA remarkably suppressed melanoma metastasis to the brain among other organs.
|
